

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/222929 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) C07K 16/28 (2006.01)
A61P 35/00 (2006.01) C07K 14/705 (2006.01)
C07K 14/725 (2006.01)

ROONEY, Cliona M.; c/o Baylor College of Medicine,
One Baylor Plaza, Houston, Texas 77030 (US). **RAMOS,**
Carlos A.; c/o Baylor College of Medicine, One Baylor
Plaza, Houston, Texas 77030 (US).

(21) International Application Number:

PCT/US2021/070461

(74) Agent: **BRUNER, Kyle**; Norton Rose Fulbright US LLP,
1301 McKinney Suite 5100, Houston, Texas 77010 (US).

(22) International Filing Date:

27 April 2021 (27.04.2021)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/015,769 27 April 2020 (27.04.2020) US

(71) Applicant: **BAYLOR COLLEGE OF MEDICINE**
[US/US]; One Baylor Plaza, Houston, Texas 77030 (US).

(72) Inventors: **QUACH, David H.**; c/o Baylor College of
Medicine, One Baylor Plaza, Houston, Texas 77030 (US).

(54) Title: TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS




Figure 1

(57) Abstract: Treatment and prevention of diseases/conditions characterised by an alloreactive immune response using virus-specific immune cells, comprising a chimeric antigen receptor (CAR) or nucleic acid encoding a CAR, wherein the CAR comprises: (i) an antigen-binding domain which binds specifically to CD30, (ii) a transmembrane domain, and (iii) a signalling domain, wherein the signalling domain comprises: (a) an amino acid sequence derived from the intracellular domain of CD28, and (b) an amino acid sequence comprising an immunoreceptor tyrosine-based activation motif (ITAM), is disclosed.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))